Welcome to the IRadimed Corporation third quarter of 2023 financial results conference call. Currently, all participants are on a listen-only mode, and at the end of the call, we will conduct a question-and-answer session. As a reminder, this call is being recorded today, November 3, 2023, and contains time-sensitive information that is accurate only today. Earlier, IRadimed released its financial results for the third quarter of 2023. A copy of this press release announcing the company's earnings is available under the heading News on their website at iradimed.com. A press release copy was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov. This call is being broadcast live over the Internet on the company's website at iradimed.com, and a replay of the call will be available on the website for the next 90 days. Some of the information in today's session will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements focus on future performance, results, plans, and events and may include the company's expected future results. IRADIMED reminds you that future results may differ materially from these forward-looking statements due to several risk factors. For a description of the relevant risks and uncertainties that may affect the company's business, please see the Risk Factors section of the company's most recent reports filed with the Securities and Exchange Commission, which may be obtained free from the SEC's website at sec.gov. I would like to turn the call over to Roger Susi, President and Chief Executive Officer of IRADIMED Corporation. Mr. Susi, please go ahead. Good morning. Thank you for joining us on today's call. I'm very pleased to report our ninth consecutive record quarter, with Q3 2023 again showing our ability to execute and grow our business. This morning's press release announced third quarter 2023 revenue came in at $16.5 million, and a 23% increase over third quarter of 2022. GAAP diluted earnings per share for the third quarter were $0.40. Non-GAAP diluted earnings per share for the third quarter of 2023 was $0.43 per share, a 48% increase over Q2 of 2022. Our entire team remains strong, committed, and able to pull together to bring in orders, needed materials, production plans, delivery, and customer setup. The MRI patient vital signs monitor continues to gain acceptance and new customers, with some very large orders this past quarter. Sales of our MRI V-pump remain strong, and with the new program for field replacements of older pumps, we anticipate growth of this older product line as well. As with last quarter, we again feel comfortable raising our guidance for the year up. Q3 is typically our weakest quarter for new bookings due to the summer holidays, yet still our total backlog built year to date continues to be sizable. As I have said before, though a strong backlog provides excellent visibility and allows us to maneuver and reallocate resources as supply issues may arise, we are striving to reduce this backlog and deliver products with less customer lead time. However, we still have a bit more backlog and associated long lead times than we prefer. We recently quote domestic lead time to our customers in 90 days and international at 120, but we plan to shave off some lead time by close to 30 days in the coming quarter. This is being done through an acceleration of production and materials flow, to provide customers quicker access to the products that they have purchased. Now, I'd like to provide progress regarding our FDA efforts surrounding the 3870 MRI IV pump. Last quarter, I spoke of the massive testing that's underway here, which continues with some tests finished, while still others remain in progress. I'd like to note that the results are positive so far, and, so it's a matter of continued forward efforts and progress to, complete the testing. As further support for our internal 510(k) team, we have engaged two external support consultants, one for technical help and the other for statutory and relationship assistance. Neither is inexpensive. Still, we feel it necessary to ensure 510(k) success with a minimal amount of FDA review time. We saw such a payoff for using an external with the recent 8-month approval of another manufacturer's new IV pump. Though we've been targeting late Q1 for refiling the new 3870's 510(k). Should our new external help suggest additional or different elements that cost us additional time, but pay off with reduced FDA review time, we will consider such input carefully. Again, the hope is that such an external input should shorten the time FDA needs for clearance. Now, I'd like to recap our Q3 performance and indicate our confidence that this upward trajectory will continue. Therefore, we now announce an increase in our guidance, with the expected revenue for the year 2023 of $65-$65.5 million. We also raised the forecast of annual GAAP diluted earnings per share to $1.34-$1.37, and then $1.48-$1.41. Forty-one, excuse me. For the first quarter of 2023, we expect to report revenue of $16.9-$17.4 million, with GAAP diluted earnings per share of $0.35-$0.38, and non-GAAP diluted earnings per share of $0.38-$0.41. Now, I'd like to turn the call over to Jack Glenn, our CFO, to review the financial results for the quarter. Thank you, Roger, and good morning, everyone. As reported on a GAAP basis and non-GAAP basis, you can find a description of our non-GAAP operating measures in this morning's earnings release and a reconciliation to the GAAP measures on the last page of today's release. As we reported earlier this morning, quarter three was $0.5 million, an increase of 23% compared to the third quarter of 2022. Domestic sales increased 29% to $13.9 million, and international sales remained flat at $2.6 million. Overall, domestic revenue accounted for 85% of total revenue for Q3 of 2023, compared to 81% for Q3 of 2022. Device revenue increased 25% to $11.8 million. This was driven by a 40% increase in monitor revenue. Revenue from disposables and services increased 24% to $4.2 million for the third quarter of 2023, while our maintenance contracts were consistent at $500,000 for both periods. The gross margin was 77.8% for the 2023 quarter, compared to 78.67% for the 2022 quarter. The decrease in gross margin is primarily due to higher overhead costs and increased raw material costs. Operating expenses were $6.9 million, or 42% of revenue, compared to $6.4 million, or 47.8% of revenue for the third quarter of 2022. On a dollar basis, this increase is primarily due to higher general and administrative expenses for additional headcount, higher regulatory and legal and professional expenses, and increased benefit expenses. As a result, income from operations grew 43% to $5.9 million for the 2023 third quarter. We recognized a tax expense during the third quarter of 2023 of approximately $1,341,000, resulting in an effective tax rate of 20.9%, compared to a tax expense of approximately $810,000 in the 2022 quarter. This increase is due to higher taxable income in 2023. On a GAAP basis, net income was $0.40 per diluted share, compared to $0.27 for the 2022 quarter. On a non-GAAP basis, adjusted income was $0.43 per diluted share for the 2023 third quarter, compared to $0.27 for the third quarter of 2022. Cash from operations was $1.4 million for the three months ended September 30, 2023, down from $3.9 million for the same period in 2022. And for the three months ended September 30, 2023 and 2022, our free cash flow, a non-GAAP measure, was $1 million and $3.4 million, respectively. And with that, I will now turn the call over for questions. Operator? Thank you. We will now begin the question and answer session. To ask a question, please press star one one on your phone and wait for your name to be announced. To withdraw your question, please press star one one again. Stand by as we compile the Q&A roster. One moment, please, for questions. Our first question will come from Scott Henry of ROTH Capital Partners. Your line is open. Thank you. Good morning, and congratulations, another strong quarter. Just a couple questions. First, any thoughts on what you're seeing on the pricing environment, you know, and perhaps with the monitors, how the shift is between US and OUS? Oh, how you doing there, Scott? This is Roger. So, maybe I'll take that one. So, you know, our pricing has, you know, with the monitor specifically, you know, we increased it by negotiating a lot of the, so the previous 18 months. The largest, I think, two, those increases actually began in July, so, actually are going and, that's on the monitor. It was, you know, decent increase there. The pump increase was very, very small actually, so, relatively insignificant. So, we're seeing, you know, we're not seeing a pushback from that sort of thing, if that was your question. As far as international goes, with the monitor, monitor sales internationally are very strong, and if-... Yeah, the rate of adoption and growth in the sales internationally for the monitor has been pretty stout, both from just penetrating the countries that we had been in historically, but as well as cultivating some new areas. Some surprises in Mexico and Colombia, for example, with some nice opportunities for the monitor there. So, all in all, you know, just positive, I guess, positive things to report. Okay, great. And then on the monitor side, we know one of your competitors appears to be less focused on that segment. Has anything changed on that landscape, or do you feel still you're in a position to take share right now? Oh, good question. So, you know, they are less focused. They still have huge problems that are in the news at least weekly. So you can tell where their focus is. But we had another little manna during COVID, from them, because were they not so focused, which remains to be the case generally, but their deliveries got extremely long 'cause they had real supply chain issues, much, much greater than we did. So we see them catching up there. So that's, let's say, one point for them. But it removes one of their- one of their hurdles, but overall, the focus is still light. The size of the sales force is still lighter than it had been, and they have their hands full dealing with, let's say, bigger fish to fry. Just the same. Okay, great. Thank you, Roger. And final question, gross margin, strong in the third quarter. As we start to think about 2024, 2025 in higher volume of monitors and pumps, how do you think about, you know, 78%-79%, does that start to move in on the ceiling for gross margins? Or do you think with higher volumes, you know, could you get to that 80% level? Ah, another good question. Okay, another good question. So during COVID, you can't really see it that much, but we did lose some pricing advantage with suppliers. You know, we were paying through the nose, let's say, for a lot of components, just to get our hands on them. And so we're... Matter of fact, just the last project for a few days this week that I've had with our materials people, it's a visible impact to our raw materials costs. They're up a couple of%, so there is something there to be corrected. How long it'll take, of course, it's not gonna be like a one-quarter fix, but, that's a mandate now for this coming year in 2024. We think... You can see it, right? The semiconductor suppliers are now. Their shortages have surpluses, and they're even thinking of cutting back some output. You know, there's opportunity there to sort of recover, to expedite in an effort to get parts that were very short supply during COVID, and upped our costs to turn that back around. But it won't be quick, but you can. I'm counting on the effect over this coming year. Short answer to your question is, yeah, I hope that we'll be able to even boost our gross margin. Okay, great. Thank you for taking the questions. Great. Good to talk. Thank you. One moment, please, for our next question. Our next question will come from Frank Takkinen of Lake Street Capital Markets, LLC. Your line is open. Hey, this is Nelson Cox on for Frank. Congrats on quarter. Yeah, you mentioned Q3 being a seasonally slower quarter for orders. Was hoping to hear your expectations for Q4. Well, the flip is Q4 is usually a big quarter for us. Yeah. Q3 is conventionally light, and Q4 is conventionally strong. Last year, I think we also had a pretty strong Q1, 'cause a lot of stuff, even though we had a good Q4 last year, there was still stuff that carried over, didn't get written as far as the orders until Q1. So, yeah, I mean, we don't expect the seasonality factor to change. Got it. And then in relation to the customer announcement to discontinue service on IV pumps over seven years old, can you help us understand your installed base better to try and place context around how many of your pumps could be over seven years old? And how large could that increase per year going forward? Oh, well, I believe... Let me think. I somehow lost that number. Yeah, somewhere. I think we think that, you know, it's somewhere in that 1,500-2,000 units out there, that are in that category over 7 years. ... Yeah, so large number of pumps and, and we've had, we've quoted, you know, we've quoted, I think, close to 400, already. That kicks in at the end of December, right? So that is being a factor that might bring in some orders, certainly in the Q4, but much more so Q1 and Q2. Those will be, you know, we're gonna start seeing those turn into orders here very soon. With the, I think the strength of it being great in Q1. Got it. That's great. Thanks for the color, and congrats again. Well, thank you. Thank you. As a reminder, to ask a question, please press star one one on your phone and wait for your name to be announced. To withdraw your question, please press star one one again. One moment, please, for our next question. Our next question will come from Frank DiLorenzo of Singular Research. Your line is open. Thank you. Good morning. Can you expand on the strength you saw in the blood filtering systems this past quarter? And can you talk about to what extent you may be able to maintain growth going forward for the fourth quarter and into next year? Thank you. Okay, Jack. Okay. Yeah, well, the sales have been growing slowly, frankly, with the FMD product. You know, it's a matter of our sales force really learning what the critical call... International demand has actually grown quicker than our domestic, but the market is quite huge compared to where we're at now. So, you know, we've got a decent number, you know, on the back. It is not up to our expectations. So, I think with the U.S., with the domestic market, it's a matter of that sale is a little different to our sales folks than it is to sell a pump or a monitor. And they're learning how to come to grips with that. As they do, you know, we see different territories starting to sell FMDs, as those different reps in those territories really learn who they should be talking to. And the internationals, it seems to be a little, a little bit more quick for them. They're picking up the ball on that one a little quicker. So long runway yet for the FMD, lots of opportunity. And we hope to, over the year 2024, in the US, gain the keys and to how we position that product and to whom we position that product to increase the sales. Okay, thanks. One other question, regarding your next generation pump. Can you talk a little bit about your strategy outside the U.S. for that, as far as getting approvals and launch, kind of, the timing on that going forward? Thanks. Oh, yeah. We won't turn our guns to tame this market probably until mid-late summer. You know, that's when we'll have the capacity with our team that's working on the 510(k) to deal with making the tech file and getting our notified body on board to do that. And with the changes in Europe, you know, the MDR for products like ours, yet, the notified bodies are still kind of the logjam of the future of mandatory MDR stuff currently. So, they're taking a long time to review tech files and clear them. So an estimate of that would be mid-2025 before we'd have a CE marked pump. Now, having said that, that's probably accounts for a third of our international business. The other two thirds of it doesn't need a CE Mark, and so, you know, we'll, we'll enter those markets, you know, very soon. You know, much sooner... You know, those will enter as soon as we're launched in the US. Okay. Thank you. Thank you. Again, to ask a question, please press star one one on your phone and wait for your name to be announced. Stand by while we compile the Q&A roster. One moment. All right. All right. I -- this will end the Q&A session. I would now like to turn the conference back to Roger Susi for closing remarks. Thank you, operator. Again, it's with great pleasure that we report our Q3 2023 results, demonstrating yet another quarter of strong growth. It is also with great pride that we can guide that we expect strong performance as the year concludes. With that, I look forward to reporting our year-end success, and thank you all for participating in today's call. Thank you. This does conclude the call. You may now disconnect. Have a pleasant day and enjoy your weekend.